|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||3.1700 - 3.5000|
|52 Week Range||0.5480 - 4.9000|
|Beta (3Y Monthly)||4.46|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
CURE Pharmaceutical (CURR), an innovative drug delivery and development company, today announced Ruben Jose King-Shaw Jr. has joined its Board of Directors. King-Shaw brings significant expertise in healthcare, government and finance. King-Shaw joins the recently named chairman William (Bill) Yuan and Dr. Gene Salkind, expanding the board to six.
CURE Pharmaceutical (CURR), an innovative drug delivery and development company, today announced it has appointed William (Bill) Yuan to Chairman of the Board and Dr. Gene Salkind to its Board of Directors.
CURE Pharmaceutical (CURR), an innovative drug delivery and development company, today announced that it will host an investor presentation at the Benzinga Cannabis Capital Conference at the Eden Roc Miami Beach Hotel in Miami on January 16, 2019 at 5pm. “This conference is the ideal kick-off to 2019, which is set to be a landmark year for the cannabis industry,” said Rob Davidson, CEO of CURE Pharmaceutical. If you would like to schedule a meeting with CURE Pharmaceutical, please contact Ashley Ray at firstname.lastname@example.org.
CURE Pharmaceutical (CURR), an innovative drug delivery and development company, today announced it has secured a new registration with the Drug Enforcement Administration (DEA) as a manufacturer authorized to handle Schedule 1 controlled substances. With this license, CURE will develop and manufacture cannabinoid-based pharmaceutical products using its CUREfilm™ technology at its facility in Oxnard, Calif. “This license enables CURE to translate the research findings from our collaboration with Technion – Israel Institute of Technology into potential treatments and expand our marketable product lines,” said Jessica Rousset, Chief Operating Officer of CURE Pharmaceutical.